A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-Globin
Latest Information Update: 24 Apr 2024
At a glance
- Drugs BD 211 (Primary) ; Busulfan (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Shanghai BDgene
- 19 Apr 2024 Planned End Date changed from 23 Feb 2024 to 23 Feb 2025.
- 19 Apr 2024 Planned primary completion date changed from 23 Feb 2024 to 23 Feb 2025.
- 24 Oct 2022 Planned End Date changed from 1 Jul 2023 to 23 Feb 2024.